Durect corporation presents additional clinical data from dur-928 phase 1b trial in nash and phase 1 trial in hepatic impairment at the international liver conference 2021 (easl)

Cupertino, calif., june 23, 2021 /prnewswire/ -- durect corporation (nasdaq: drrx) today announced the presentation of additional clinical data from a dur-928 phase 1b trial in non-alcoholic steatohepatitis (nash) and a phase 1 trial in subjects with hepatic impairment (hi) as part of two posters at the 2021 international liver conference (easl) being held virtually june 23-26, 2021.
DRRX Ratings Summary
DRRX Quant Ranking